Current state and issues related to cell therapy under the Act on the Safety of Regenerative Medicine

In May the 2013, Regenerative Medicine Promotion Act was enacted in order to promote regenerative medicine in Japan. Based on this Act, in November 2014, the Act on the Safety of Regenerative Medicine, which ensured the safety of regenerative medicine, was put into effect. The Act on the Safety of R...

Full description

Saved in:
Bibliographic Details
Published inPersonalized medicine universe Vol. 7; pp. 37 - 38
Main Author Tobita, Morikuni
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.07.2018
Subjects
Act on Safety for Regenerative Medicine
Clinical research
Private practice
Regenerative medicine
Private practice
Clinical research
Act on Safety for Regenerative Medicine
Regenerative medicine
Online AccessGet full text

Cover

More Information
Summary:In May the 2013, Regenerative Medicine Promotion Act was enacted in order to promote regenerative medicine in Japan. Based on this Act, in November 2014, the Act on the Safety of Regenerative Medicine, which ensured the safety of regenerative medicine, was put into effect. The Act on the Safety of Regenerative Medicine was intended to promote the swift and safe provision and promulgation of regenerative medicine, and it applies to both clinical research and private practice that utilizes regenerative medicine. In this review, an overview of the Act on the Safety of Regenerative Medicine is introduced, and the current state of this act and future issues are discussed.
ISSN:2186-4950
2186-4950
DOI:10.1016/j.pmu.2018.04.003